A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)
ccRCC Post Nephrectomy (Adjuvant Therapy)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
DR MARNIZA SAAD
marniza@ummc.edu.my
CONTACT
SC: Cryst Sari: 03-79492120 (Research Room)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
Facebook
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
DR SOO HOO HWOEI FEN
hwoeifen@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
Facebook